Status:

RECRUITING

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Lead Sponsor:

Rocket Pharmaceuticals Inc.

Conditions:

Danon Disease

Eligibility:

MALE

8+ years

Phase:

PHASE2

Brief Summary

This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 is...

Detailed Description

The study is a single arm Phase 2 clinical trial to characterize the safety and efficacy of RP-A501, a recombinant adeno-associated serotype 9 (rAAV9 capsid containing the human lysosome-associated me...

Eligibility Criteria

Inclusion

  • Key
  • Documentation of a pathogenic or likely pathogenic variant of the LAMP2 gene.
  • Male.
  • Age ≥8 years.
  • Evidence of left ventricular hypertrophy with preserved systolic function phenotype as defined by each of the following:
  • Abnormal thickening of Left ventricular wall,
  • Left ventricular ejection fraction (LVEF) ≥ 50%.
  • New York Heart Association (NYHA) Class II to III.
  • High sensitivity Troponin I (hsTnI) ≥20% above the upper limit of normal (ULN)
  • Ability to comply with study procedures including investigational therapy and follow-up evaluations.
  • Key

Exclusion

  • Anti-AAV9 neutralizing antibody titer \>1:40.
  • Severe heart failure or requirement for advanced therapies.
  • History of intracardiac thrombosis or arterial thromboembolic events including stroke, transient ischemic attack (TIA), acute coronary syndrome, myocardial infarction or unstable angina.
  • Prior cardiac or other organ (lung, liver, other) transplantation.

Key Trial Info

Start Date :

September 5 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2032

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT06092034

Start Date

September 5 2023

End Date

April 1 2032

Last Update

October 7 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

University of California, San Diego

La Jolla, California, United States, 92037

2

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

3

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

4

German Heart Center Munich

Munich, Germany

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease | DecenTrialz